Advertisement
Person › Details
Cedric Ververken (Confo Therapeutics N.V.)
Ververken, Cedric (Confo Therapeutics 201610– CEO before Ablynx)
Organisation | Confo Therapeutics N.V. | |
Former/major organisation | Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX) | |
Group | Sanofi (Group) [since May 2011] | |
Product | drug discovery | |
Product 2 | Confo® technology | |
Record changed: 2023-03-09 |
Advertisement
More documents for Cedric Ververken
- [1] Confo Therapeutics N.V.. (3/2/23). "Press Release: Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554". Ghent....
- [2] Confo Therapeutics N.V.. (5/7/19). "Press Release: Confo Therapeutics Raises €30 Million in Series A Financing". Ghent....
- [3] Confo Therapeutics N.V.. (1/3/19). "Press Release: Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology". Ghent....
- [4] Confo Therapeutics N.V.. (12/6/18). "Press Release: Confo Therapeutics Appoints Frank Landolt as Its Chief Counsel Legal & Intellectual Property". Ghent....
- [5] Confo Therapeutics N.V.. (2/20/18). "Press Release: Confo Therapeutics Is Awarded a EUR 1M Grant to Increase Its Screening Capabilities". Ghent....
- [6] Confo Therapeutics N.V.. (12/19/17). "Press Release: Confo Therapeutics Enters into Drug Discovery Collaboration with Roche". Ghent....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top